

Table

Common P/LP Somatic Variants (N=126), n (%)	Fusions (N-125), Identified on (DNA) vs. (RNA) * denotes novel fusion in OS	Incidental P/LP Germline Variants from T/N-matched Sequencing (n=71), n (%)	Prevalence of Immune Markers (N=125 for TMB-H, 113 for MSI-H, 55 for PD-L1), n (%)
TP53: 4 (35%)	EWSR1-PATZ1 (DNA)		
RB1: 22 (17%)	EWSR1-CREB3L1(DNA)		
CDKN2A: 21 (17%)	TP53-DAH2 (DNA)		
CDKN2B: 19 (15%)	FGFR3-TACC3 (DNA)*		
UGT1A1: 19 (15%)	KAT6A-TRIM35(RNA)*		
CDK4: 18 (14%)	DSCR4-ERG (DNA)*	MUTYH: 2 (2.8%)	TMB-H: 2 (1.8%)
MAP: 16 (13%)	TP53-TBC1D22B (DNA)*	PMS2: 2 (2.8%)	MSI-H: 1 (0.8%)
ATRX: 14 (11%)	HMGA2-ARNTL2(RNA)*	RB1: 1 (1.4%)	PD-L1+: 6 (11%)
FLCN: 14 (11%)	EWSR1-PLA2G6(DNA)*		
NCOR1: 14 (11%)	FUS-NFATC2(RNA)*		
PTEN: 11 (8.7%),			
SLC47A2: 11 (8.7%)			
YEATS4: 11 (8.7%)			

P/LP=pathogenic/likely pathogenic; T/N=tumor/normal; TMB-H=tumor mutational burden-high, defined as ≥ 10 mutations/megabase; MSI-H=microsatellite instability-high